Extranodal Nk T-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Extranodal Nk T-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type [Phase 2]
Phase 2 clinical trial of IMC-001 in subjects with relapsed or refractory extranodal NK/T-cell lymphoma, nasal type; the study is currently …
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH) [Phase 1, Phase 2]
An update on a Phase 1/Phase 2 trial of MEPL-G (mitoxantrone liposome, etoposide, dexamethasone, pegaspargase, and golodocitinib) for extran…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating tislelizumab plus zeprumetostat for relapsed or refractory NK/T-cell lymphoma is listed as not yet rec…
-
CLINICAL_TRIALS research · 2026-02-04Clinical Trial Update: Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma [Phase 2]
A Phase 2 trial compares adding golidocitinib to a P-GemOx regimen plus a PD-1 inhibitor against P-GemOx plus a PD-1 inhibitor as first-line…
-
CLINICAL_TRIALS research · 2025-05-01Clinical Trial Update: A Study Comparing of P-GEMD Regimen Versus P-Gemox Regimen With Untreated Early-Stage NUAT or Advanced-Stage ENKTL. [Phase 3]
A Phase 3 trial comparing the P-GEMD regimen with the P-Gemox regimen in untreated early-stage or advanced extranodal NK/T-cell lymphoma, st…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-04-29Clinical Trial Update: Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies [Phase 1]
This clinical trial update describes a Phase 1 dose-escalation and dose-expansion study of anti-CD7 allogeneic CAR T-cells (WU-CART-007) in …
-
CLINICAL_TRIALS research · 2025-02-13Clinical Trial Update: Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma [Phase 2]
This entry reports a Phase 2 clinical trial evaluating a combination of sintilimab, pegaspagase, and GemOx (gemcitabine and oxaliplatin) for…
-
CLINICAL_TRIALS trial_result · 2024-04-17Clinical Trial Update: B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial update of B-MAD chemotherapy in newly diagnosed Extranodal NK/T-cell Lymphoma completed.
-
CLINICAL_TRIALS trial_result · 2023-03-17Clinical Trial Update: Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) in the Treatment of Untreated Early Non-upper Respiratory Tract or Advanced Extranodal NK/T-cell Lymphoma [Phase 2]
Phase 2 trial evaluating Pegaspargase with gemcitabine, etoposide, liposomal mitoxantrone, and dexamethasone (P-GEMD) for untreated early no…
-
CLINICAL_TRIALS trial_result · 2022-05-04Clinical Trial Update: Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms [Phase 2]
Phase 2 study of BGB-A317 (tislelizumab) in adults with relapsed or refractory mature T- and NK-cell neoplasms has completed, with results p…
-
CLINICAL_TRIALS trial_result · 2022-04-29Clinical Trial Update: VT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T Cell Lymphoma Patients [Phase 2]
Phase 2 clinical trial update for VT-EBV-N in EBV-positive extranodal NK/T-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2022-04-14Clinical Trial Update: Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL [Phase 1, Phase 2]
Phase 1/2 trial evaluating sintilimab combined with chidamide for refractory and relapsed extranodal NK/T-cell lymphoma (ENKTL) has complete…
-
CLINICAL_TRIALS trial_result · 2022-04-14Clinical Trial Update: Sintilimab in Combination With Chidamide in Newly Diagnosed ENKTCL [Phase 2]
A Phase 2 clinical trial evaluating sintilimab in combination with chidamide for newly diagnosed extranodal NK/T-cell lymphoma (ENKTCL) focu…
-
CLINICAL_TRIALS trial_result · 2022-02-24Clinical Trial Update: Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL [Phase 2]
Phase 2 trial evaluating anti-PD-1 antibody plus P-GEMOX chemotherapy with radiotherapy for high-risk, early-stage Extranodal NK/T-Cell Lymp…
-
CLINICAL_TRIALS trial_result · 2021-12-08Clinical Trial Update: Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL [Phase 2]
Phase 2 clinical trial update evaluating radiotherapy with anti-PD-1 therapy in low-risk extranodal NK/T-cell lymphoma, nasal type, in early…
-
CLINICAL_TRIALS trial_result · 2021-06-08Clinical Trial Update: GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma [Phase 2]
Phase 2 clinical trial update for GPED in relapsed/refractory or advanced Extranodal NK/T-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2020-12-17Clinical Trial Update: Efficacy and Safety Evaluation of IBI308 in Patients With Extranodal NK/T Cell Lymphoma Patients [Phase 2]
Phase 2 clinical trial update evaluating efficacy and safety of IBI308 in extranodal NK/T cell lymphoma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-10-22Clinical Trial Update: VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT) [Phase 2]
Phase 2 trial evaluating a combination chemotherapy regimen (VP-16, Ifosfamide, Dexamethasone, L-asparaginase) in patients with Extranodal N…
-
CLINICAL_TRIALS trial_result · 2020-07-23Clinical Trial Update: Pegaspargase-COEP Chemotherapy Combined With Radiotherapy for Extra-nodal NK/T Cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating pegaspargase-COEP chemotherapy with radiotherapy for extranodal NK/T-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2020-05-07Clinical Trial Update: Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma [Phase 2]
Phase 2 trial evaluating sintilimab in combination with decitabine for relapsed/refractory or advanced extranodal NK/T-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2020-04-07Clinical Trial Update: Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL [Phase 2]
Phase 2 trial update exploring the combination of Basiliximab and Pegaspargase for Extranodal NK/T-cell Lymphoma.
-
CLINICAL_TRIALS research · 2018-07-26Clinical Trial Update: Tofacitinib Combined With Chidamide in R/R ENKTCL [Phase 2]
A Phase 2 clinical trial is evaluating the combination of tofacitinib with chidamide in relapsed/refractory Extranodal NK/T-cell lymphoma; c…
-
CLINICAL_TRIALS trial_result · 2018-05-09Clinical Trial Update: P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens [Phase 2]
A Phase 2 trial evaluating the P-Gemox chemotherapy regimen as first-line treatment for extranodal NK/T-cell lymphoma has been terminated.
-
CLINICAL_TRIALS trial_result · 2017-05-17Clinical Trial Update: Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer [Phase 2]
Phase 2 trial evaluating haploidentical donor bone marrow transplantation in patients with high-risk hematologic cancers; results completed …
-
CLINICAL_TRIALS trial_result · 2016-09-05Clinical Trial Update: Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin in Untreated NK/T Cell Lymphoma [Phase 2]
A Phase 2 trial evaluating a regimen of bortezomib with gemcitabine, ifosfamide and oxaliplatin in untreated Extranodal NK/T-cell lymphoma w…